<DOC>
	<DOCNO>NCT00927953</DOCNO>
	<brief_summary>This study test drug call MGAWN1 treatment West Nile infection .</brief_summary>
	<brief_title>Treatment West Nile Virus With MGAWN1</brief_title>
	<detailed_description>The objective study evaluate safety , efficacy , pharmacokinetics MGAWN1 subject West Nile Fever syndrome compatible West Nile Neuroinvasive Disease ( WNND ) [ encephalitis , meningitis , acute flaccid paralysis ] . Subjects enrol base syndrome compatible WNND , need document West Nile virus infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>West Nile Fever</mesh_term>
	<mesh_term>Central Nervous System Infections</mesh_term>
	<criteria>1 . Provide write informed consent 2 . Be &gt; =18 year age time enrollment 3 . Have West Nile Fever define : 1. temperature &gt; 38°C , headache , AND 2. positive diagnostic test WNV Ribonucleic acid Immunoglobulin M serum cerebrospinal fluid ( CSF ) OR West Nile Neuroinvasive Disease ( include neurological sign and/or symptom West Nile meningitis , encephalitis , and/or acute flaccid paralysis ) , define : • West Nile encephalitis ( must meet criterion b ) 1 . Encephalopathy ( depress alter level consciousness , lethargy , personality change last 24 hour ) 2 . CSF pleocytosis &gt; =5 cells/mm^3 AND/OR • West Nile meningitis ( must meet criterion c ) 3 . Clinical sign meningeal inflammation , include nuchal rigidity , Kernig Brudzinski sign , photophobia , phonophobia 4 . CSF pleocytosis &gt; =5 cells/mm^3 AND/OR • Acute flaccid paralysis ( must meet criterion e f ) 5 . Acute onset limb weakness mark progression 48 hour 6 . Two follow condition : asymmetry weakness areflexia hyporeflexia affect limb ( ) absence pain , paresthesia , numbness affect limb ( ) CSF pleocytosis &gt; =5 cells/mm^3 CSF elevate protein level ( 4.5 g/L ) electrodiagnostic study consistent anterior horn cell process abnormal increase signal anterior gray matter document spinal cord magnetic resonance image 4 . Have epidemiological factor consistent West Nile Virus infection ( must meet criterion b ) : 1 . Appropriate time year West Nile Virus transmission region 2 . Travel history region West Nile Virus active 5 . Develop sign and/or symptom within 14 day study enrollment . 6 . If female childbearing potential male sexual relationship female childbearing potential , agree ( partner agree ) practice abstinence use 2 follow method contraception 120 day ( approximately 4 month ) study drug administration : 1 . Oral contraceptive , form hormonal birth control include hormonal vaginal ring transdermal patch 2 . An intrauterine device 3 . Barrier contraception ( condom ) spermicide ( i.e. , female subject ensures use male partner [ ] ) 4 . Any equivalent method contraception ( judged investigator )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>West Nile virus</keyword>
	<keyword>WNV</keyword>
	<keyword>Encephalitis</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Acute Flaccid Paralysis</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>WNND</keyword>
	<keyword>West Nile Fever</keyword>
	<keyword>WNF</keyword>
</DOC>